Abivax S.A. (ABVX) Form 6-K — Jun 2, 2026
Abivax SA announced positive topline results from its Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis. Both the 25 mg and 50 mg doses met the primary endpoint of clinical remission at Week 44, with placebo-adjusted deltas of 39.3% and 40.3% respectively, against a 10.4% placebo rate. The drug also met all key secondary endpoints, including endoscopic improvement, endoscopic remission, and sustained clinical remission, with p-values <0.0001 for all measures. The safety profile was favorable, with no new safety signals observed and low discontinuation rates due to adverse events.
Key figures
- P Value
- <0.0001
- Trial Duration
- 44 weeks
- Total Participants
- 580
- Ndasubmission Target
- Q4 2026
- Placebo Adjusted Delta 25mg
- 39.3%
- Placebo Adjusted Delta 50mg
- 40.3%
- Clinical Remission Rate 25mg
- 50.8%
- Clinical Remission Rate 50mg
- 51.3%
- Clinical Remission Rate Placebo
- 10.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.